Clinical Trial Update: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ABT-199 in relapsed or refractory multiple myeloma (Phase 1/Phase 2) with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• ABT-199 (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-04-10